AR088564A1 - PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3 - Google Patents

PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3

Info

Publication number
AR088564A1
AR088564A1 ARP120104036A ARP120104036A AR088564A1 AR 088564 A1 AR088564 A1 AR 088564A1 AR P120104036 A ARP120104036 A AR P120104036A AR P120104036 A ARP120104036 A AR P120104036A AR 088564 A1 AR088564 A1 AR 088564A1
Authority
AR
Argentina
Prior art keywords
compound
formula
produce
catalyst
reduction
Prior art date
Application number
ARP120104036A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR088564A1 publication Critical patent/AR088564A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Catalysts (AREA)

Abstract

Reivindicación 1: Un proceso para la preparación del compuesto de fórmula (1), que comprende: (a) reacción del compuesto de fórmula (2), con un reactivo protector de acetonida seleccionado entre el grupo que consiste en 2,2-dimetoxipropano, 2,2-dietoxipropano, 2-metoxipropeno y acetona, para producir el compuesto de fórmula (3); (b) reducción del compuesto de fórmula (3) con un agente reductor a una temperatura de 0ºC a 40ºC para producir el compuesto de fórmula (4); (c) oxidación del compuesto de fórmula (4) con un agente oxidante en presencia de un disolvente y de un catalizador para producir el compuesto de fórmula (5); (d) reacción del compuesto de fórmula (5) con un compuesto de fosfato de fórmula (6) para producir el compuesto de fórmula (7); (e) reducción del compuesto de fórmula (7) en presencia de un catalizador para producir el compuesto (8); (f) reacción del compuesto de fórmula (8) con un ácido para producir el compuesto de fórmula (9); (g) reducción del compuesto de fórmula (9) en presencia de un catalizador para producir el compuesto de fórmula (1); en el que cada uno de P¹ y P² se selecciona independientemente entre el grupo que consiste en Ac, Bn, Boc, Bz, Cbz, DMPM, FMOC, Ns, Moz, y Ts; y R¹ se selecciona entre el grupo que consiste en alquilo C₁₋₆, bencilo y fenilo.
ARP120104036A 2011-10-27 2012-10-26 PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3 AR088564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552200P 2011-10-27 2011-10-27

Publications (1)

Publication Number Publication Date
AR088564A1 true AR088564A1 (es) 2014-06-18

Family

ID=48168357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104036A AR088564A1 (es) 2011-10-27 2012-10-26 PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3

Country Status (7)

Country Link
US (4) US9809536B2 (es)
EP (1) EP2771006B1 (es)
JP (1) JP6088535B2 (es)
AR (1) AR088564A1 (es)
ES (1) ES2584427T3 (es)
TW (1) TW201323406A (es)
WO (1) WO2013062878A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法
CN117695286A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
KR20250095747A (ko) 2017-06-06 2025-06-26 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 투약
CA3098536A1 (en) 2018-05-23 2019-11-28 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
EP4545072A3 (en) 2018-12-05 2025-07-02 Urovant Sciences GmbH Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
WO2020188505A1 (en) 2019-03-18 2020-09-24 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
US12215359B2 (en) 2019-05-01 2025-02-04 Codexis, Inc. Engineered glucose dehydrogenases and methods for the reductive amination of ketone and amine compounds
MX2022004017A (es) * 2019-10-02 2022-05-02 Abbott Diabetes Care Inc Deteccion de analitos por medio de interruptores de proteinas.
CN112708644B (zh) * 2019-10-25 2024-05-28 弈柯莱生物科技(集团)股份有限公司 氟苯尼考中间体的制备方法
CN112176007B (zh) * 2020-10-12 2022-07-22 上海医药工业研究院 一种氨基醇手性中间体的制备方法
MX2023007413A (es) 2020-12-22 2023-07-21 Urovant Sciences Gmbh Metodos para monitorear digoxina con el uso de vibegron para tratar veiiga hiperactiva.
JP2024516061A (ja) 2021-02-16 2024-04-12 ウロバント サイエンシズ ゲーエムベーハー ビベグロンによる心不全の処置方法
GB202113588D0 (en) * 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
CN113816917B (zh) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 一种维贝格龙中间体的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
US8748143B2 (en) * 2007-09-13 2014-06-10 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2329014B1 (en) 2008-08-29 2014-10-22 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
IN2012DN02782A (es) 2009-10-07 2015-09-18 Merck Sharp & Dohme
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ3アドレナリン作動性受容体アゴニスト
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
CN106479990B (zh) 2011-11-18 2020-09-18 科德克希思公司 用于制备羟基取代的氨基甲酸酯的生物催化剂
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法

Also Published As

Publication number Publication date
US20180029981A1 (en) 2018-02-01
US9809536B2 (en) 2017-11-07
EP2771006A4 (en) 2015-04-15
US20140242645A1 (en) 2014-08-28
US11767292B2 (en) 2023-09-26
US20220073459A1 (en) 2022-03-10
EP2771006A1 (en) 2014-09-03
US11124478B2 (en) 2021-09-21
EP2771006B1 (en) 2016-05-25
ES2584427T3 (es) 2016-09-27
WO2013062878A1 (en) 2013-05-02
JP6088535B2 (ja) 2017-03-08
TW201323406A (zh) 2013-06-16
US20200290962A1 (en) 2020-09-17
US10577316B2 (en) 2020-03-03
JP2015501319A (ja) 2015-01-15

Similar Documents

Publication Publication Date Title
AR088564A1 (es) PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
BR112014030365A2 (pt) síntese de composto antiviral
EA201690172A1 (ru) Полиморф ингибиторов syk
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
NZ716598A (en) Anthelmintic compounds and compositions and method of using thereof
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
TR201906413T4 (tr) Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi.
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
ES2721659T3 (es) Aparato para generar 1-metilciclopropeno
EA201590770A1 (ru) Ингибиторы вируса гепатита с
PE20131098A1 (es) Proedimiento de preparacion de la sal de l-arginina de perindoprilo
PE20140917A1 (es) Sintesis de derivados de 2-carboxamida-cicloamino-urea
AR088358A1 (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos
EP3018125A4 (en) NOVEL CONNECTION, REFERENCE TO ORGANIC CATION TRANSPORTER 3 AND DISORDER OF THE ORGANIC CATION TRANSPORTATION ACTIVITY 3
BR112015006370A2 (pt) meios e métodos para tratamento de tumores sólidos
AR081732A1 (es) Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
AR081804A1 (es) Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades
BR112014013411A2 (pt) derivados de ureia cíclica como antagonistas de receptores androgênicos
AR087345A1 (es) Metodos para la preparacion de compuestos de tiofeno
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью

Legal Events

Date Code Title Description
FG Grant, registration